NCT03666221 2018-09-11Nimotuzumab for Recurrent Nasopharyngeal CarcinomaFujian Cancer HospitalPhase 2 Unknown67 enrolled
NCT02095119 2015-04-14A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical CancerNational Institute of CancerologíaPhase 1/2 Completed15 enrolled